Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy

Cytomegalovirus (CMV) infects most of the world population. This study is to understand if chemotherapy will increase the chance of reactivating CMV. The results may help us in determining when treatment is needed and perhaps Why is it needed.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Cytomegalovirus Neoplasms

Age range

20 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mackay Memorial Hospital

Taipei, 10449, Taiwan

About this study

Despite CMV reactivation has been clearly described in patients underwent transplantation, this phenomenon has not been studied in patients undergoing chemotherapy. Our purpose is to understand if CMV number increases in monocytic leukocytes during chemotherapy and how is the host response to that changes.

Virus load will be studied by quantitative PCR, host response will be studied by measuring patient's anti-CMV IgG, CMV-associated symptoms, serum IFN-r and TNF-a.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

clinical diagnosis of any cancer
chemotherapy is needed for more than 6 months
age>20 years old

Exclusion criteria

those who do not agree to participate

Sponsors and collaborators

Lead sponsor

Mackay Memorial Hospital

Other

Registry information

Important dates

Study start: 2005
Study completion: 2006
First posted: Aug 21, 2006
Registry last updated: Aug 21, 2006

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed